Assis, Rafael
Jain, Aarti
Nakajima, Rie
Jasinskas, Algis
Khan, Saahir
Davies, Huw
Corash, Laurence
Dumont, Larry J.
Kelly, Kathleen
Simmons, Graham
Stone, Mars
Di Germanio, Clara
Busch, Michael
Felgner, Philip L.
Funding for this research was provided by:
Defense Threat Reduction Agency (HDTRA1-16-C-0009)
University of California, Irvine (CARFT-COVID)
Article History
Received: 1 December 2020
Accepted: 19 March 2021
First Online: 6 April 2021
Competing interests
: The coronavirus antigen microarray is intellectual property of the Regents of the University of California that is licensed for commercialization to Nanommune Inc. (Irvine, CA, USA), a private company for which Philip L. Felgner is the largest shareholder and several co-authors (de Assis, Jain, Nakajima, Jasinskas, Davies, and Khan) also own shares. Nanommune Inc. has a business partnership with Sino Biological Inc. (Beijing, China) which expressed and purified the antigens used in this study. Laurence Corash; Larry J. Dumont; Kathleen Kelly; Graham Simmons; Mars Stone; Clara Di Germanio and Michael Busch have no conflict of interest.